KR960037046A - Ophthalmic Formulation for the Treatment of Myopia and Glaucoma Including Dopamine Receptor Stimulant - Google Patents

Ophthalmic Formulation for the Treatment of Myopia and Glaucoma Including Dopamine Receptor Stimulant Download PDF

Info

Publication number
KR960037046A
KR960037046A KR1019950007712A KR19950007712A KR960037046A KR 960037046 A KR960037046 A KR 960037046A KR 1019950007712 A KR1019950007712 A KR 1019950007712A KR 19950007712 A KR19950007712 A KR 19950007712A KR 960037046 A KR960037046 A KR 960037046A
Authority
KR
South Korea
Prior art keywords
ophthalmic formulation
dopamine receptor
receptor stimulant
treatment
stimulant
Prior art date
Application number
KR1019950007712A
Other languages
Korean (ko)
Other versions
KR0159640B1 (en
Inventor
이용희
최윤정
서미경
이창호
김인철
민병무
Original Assignee
성재갑
주식회사 Lg 화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성재갑, 주식회사 Lg 화학 filed Critical 성재갑
Priority to KR1019950007712A priority Critical patent/KR0159640B1/en
Publication of KR960037046A publication Critical patent/KR960037046A/en
Application granted granted Critical
Publication of KR0159640B1 publication Critical patent/KR0159640B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형에 관한 것으로서, 도파민 수용기 자극제 및, 사이클로 덱스트린 또는 그의 유도체를 필수 구성 성분으로 하는 안과 제형은, 눈의 생리적 pH로 조절되어 안구에 자극을 주지 않으면서, 점안 투여시 혈장으로의 이행이 적으며 망막 등 안구 각 조직으로의 이행이 우수하므로, 점안 투여에 의한 치료 및 녹내장 치료에 있어서 보다 유효하게 사용될 수 있다.The present invention relates to an ophthalmic formulation for treating myopia and glaucoma comprising a dopamine receptor stimulant, wherein the ophthalmic formulation comprising the dopamine receptor stimulant and cyclodextrin or a derivative thereof as an essential component is controlled by the physiological pH of the eye and stimulated to the eye. Without omission, since the transition to the plasma during eyedrop administration is excellent and the transition to eye tissues such as the retina is excellent, it can be used more effectively in the treatment by the topical administration and glaucoma treatment.

Description

도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형Ophthalmic Formulation for the Treatment of Myopia and Glaucoma Including Dopamine Receptor Stimulant

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (10)

도파민 수용기 자극제 및, 사이클로덱스트린 또는 그의 유도체를 필수 구성 성분으로 하는 안과 제형.An ophthalmic formulation comprising a dopamine receptor stimulant and a cyclodextrin or a derivative thereof as an essential component. 제1항에 있어서, 도파민 수용기 자극제가 도파민 수용기 1과 2 자극제 및 도파민 수용기 2 자극제의 적어도 하나임을 특징으로 하는 안과 제형.The ophthalmic formulation of claim 1, wherein the dopamine receptor stimulant is at least one of a dopamine receptor 1 and 2 stimulant and a dopamine receptor 2 stimulant. 제1항에 있어서, 도파민 수용기 자극제가 브로모트립틴인 안과 제형.The ophthalmic formulation of claim 1, wherein the dopamine receptor stimulant is bromotriptin. 제3항에 있어서, 브로모크리틴의 농도가 0.01 내지 0.5%(w/v)인 안과 제형.The ophthalmic formulation according to claim 3, wherein the concentration of bromocritin is 0.01 to 0.5% (w / v). 제1항에 있어서, 사이클로덱스트린 또는 그의 유도체가 5 내지 50%(w/v)인 안과 제형.The ophthalmic formulation of claim 1, wherein the cyclodextrin or derivative thereof is 5-50% (w / v). 제1항에 있어서, 사이클로덱스트린 또는 그의 유도체가 β-사이클로덱스트린인 안과 제형.The ophthalmic formulation of claim 1, wherein the cyclodextrin or derivative thereof is β-cyclodextrin. 제1항에 있어서, 수용성 폴리머를 더욱 포함하는 안과 제형.The ophthalmic formulation of claim 1 further comprising a water soluble polymer. 제7항에 있어서, 수용성 폴리머가 폴리비닐 피롤리돈, 폴리비닐 알코올, 하이드록시프로필 셀룰로오즈 및 하이알루론산으로 구성되는 그룹으로부터 선택된 적어도 하나인 안과 제형.8. The ophthalmic formulation of claim 7, wherein the water soluble polymer is at least one selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol, hydroxypropyl cellulose and hyaluronic acid. 제7항에 있어서, 수용성 폴리머가 0.01 내지 7%(w/v)인 안과 제형.8. The ophthalmic formulation of claim 7, wherein the water soluble polymer is from 0.01 to 7% (w / v). 제1항 내지 제9항의 어느 한 항의 안과 제형을 투여하여 근시 또는 녹내장을 치료하는 방법.A method of treating myopia or glaucoma by administering the ophthalmic formulation of claim 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950007712A 1995-04-03 1995-04-03 Ophthalmic formulation containing dopamine receptor agonist for treatment of myopia and giaucoma KR0159640B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950007712A KR0159640B1 (en) 1995-04-03 1995-04-03 Ophthalmic formulation containing dopamine receptor agonist for treatment of myopia and giaucoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950007712A KR0159640B1 (en) 1995-04-03 1995-04-03 Ophthalmic formulation containing dopamine receptor agonist for treatment of myopia and giaucoma

Publications (2)

Publication Number Publication Date
KR960037046A true KR960037046A (en) 1996-11-19
KR0159640B1 KR0159640B1 (en) 1998-12-01

Family

ID=19411437

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950007712A KR0159640B1 (en) 1995-04-03 1995-04-03 Ophthalmic formulation containing dopamine receptor agonist for treatment of myopia and giaucoma

Country Status (1)

Country Link
KR (1) KR0159640B1 (en)

Also Published As

Publication number Publication date
KR0159640B1 (en) 1998-12-01

Similar Documents

Publication Publication Date Title
Toda et al. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren's syndrome
DE69828993T2 (en) CONTROLLED DELIVERY OF PHARMACEUTICALS IN THE FRONT EYE CHAMBER
DE60118859T2 (en) Pharmaceutical composition containing trehalose for ophthalmic use
JPS6145608B2 (en)
JP2021165311A (en) High elasticity hyaluronan compositions and methods of use thereof
DE69634414D1 (en) USE OF SUBSTITUTED ISOCHINOLINSULFONYL COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF GLUCKOM AND OKULAR ISCHEMIA
DE60022544D1 (en) TREATMENT OF EYE DISEASES
EP0822822A1 (en) Controlled release of miotic and mydriatic drugs in the anterior chamber
Fisher et al. Allergic contact sensitivity to benzalkonium chloride: cutaneous, ophthalmic, and general medical implications
KR960700039A (en) Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor
KR20050105439A (en) Medicinal composition for ophthal use containing acetylated hyaluronic acid
JPH04210922A (en) Ophthalmic therapeutic substance
MXPA04005390A (en) Heparin-containing ophthalmic agent.
CA2282757A1 (en) Opthalmic composition
US5200180A (en) Pharmaceutical composition for the treatment of the human eye
WO2002078564A2 (en) Method for creating a separation of posterior cortical vitreous from the retina of the eye
JPH08511024A (en) Methods and compositions for reducing intraocular pressure
MXPA03011613A (en) Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome.
EP3419590B1 (en) Hyaluronic acid conjugate
KR960037046A (en) Ophthalmic Formulation for the Treatment of Myopia and Glaucoma Including Dopamine Receptor Stimulant
JPH01502829A (en) Composition for topical treatment of glaucoma or ocular hypertension
US6071875A (en) TGFα for the treatment of ocular hypertension and glaucoma
CA2114239C (en) Pharmaceutical composition containing carbachol and other cholinergic substances
JP2787131B2 (en) Aqueous suspension
JPH08175985A (en) Ophthalmic solution

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040624

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee